As FDA Review Looms, Drug Cos. Defend Vytorin Study

By Shannon Henson

Law360, New York (January 24, 2008, 12:00 AM ET) -- Merck & Co. and Schering-Plough Corp. continued to defend a controversial study of their Vytorin and Zetia cholesterol treatments Friday on the heels of the U.S. Food and Drug Administration announcing that it will review the study once it receives the final results.

The FDA said that it will take about six months to fully evaluate the data once it receives the final so-called Enhance study.

“After reviewing the data from the Enhance study, and considering all other available information about the link between LDL (bad...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles